Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.…
Malin Corporation plc (MLC.IR) Seasonal returns chart
Malin (ISE: MLC) is listed on Euronext Dublin, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 6.000 EUR on 19 November 2026, down 30.6% over 52 weeks. Its 52-week range is 5.950 EUR to 9.300 EUR, and it trades at the bottom of that range.
Its market capitalisation is 25.96M EUR.
Malin reports return on equity of 0.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 12.90M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 15.50 EUR is 158.3% above the current price.
No upcoming events tracked.